Imaging interactions between stress hormones and opioid receptors in cocaine use disorder
Official title: Imaging Corticotrophin-releasing Factor (CRF) X Nociceptive Opioid Peptide (NOP) Interactions in Cocaine Use Disorders (Aim 1)
Run by University of Pittsburgh · NCT05008146 · Data updated 2026-11-12
This study is testing how stress hormones and certain brain receptors interact in people with cocaine use disorder to see if these interactions can help predict relapse.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | University of Pittsburgh Academic / other |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Status | Recruiting |
| Started | December 31, 2020 |
| Main results expected | September 1, 2028 |
| Study ends | September 1, 2028 |
| Registry record updated | July 6, 2026 |
| Trial ID | NCT05008146 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are males and females aged 18 to 55 who meet DSM-5 criteria for cocaine use disorder without other psychiatric or addictive disorders.
✕Probably not a fit
Patients with current or past severe medical, endocrine, or neurological illnesses, or those with other significant psychiatric disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study utilizes [C-11]NOP-1A positron emission tomography (PET) to investigate the interactions between nociceptive opioid peptide (NOP) receptors and cortisol/corticotrophin releasing factor (CRF) in individuals with cocaine use disorder (CUD) and healthy controls. It aims to understand how these interactions may predict relapse in CUD patients by examining neurochemical changes associated with stress and resilience. Participants will undergo baseline and post-hydrocortisone PET scans to assess NOP receptor binding and its response to stress. The findings could provide insights into the neurobiological mechanisms underlying relapse in CUD.
Why it matters
Potential benefit: If successful, this study could lead to the development of targeted medications to prevent relapse in individuals with cocaine use disorder.
How similar studies have gone: While studies have explored neurochemical mechanisms in addiction, this specific approach using NOP receptor imaging in CUD is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Cocaine use disorders (CUD) 1. Males or females between 18 and 55 years old 2. Fulfil DSM-5 criteria for cocaine use disorder 3. No other current DSM-5 psychiatric or addictive disorders (such as major depressive disorder, bipolar disorders, psychotic disorders, etc.,) 4. No current abuse (six months) of opiates, sedative-hypnotics, amphetamines, MDMA, etc., as well as moderate to severe alcohol or cannabis use (twice a week). Nicotine use will be quantified and controlled between groups using the Fagerstrom Test for Nicotine Dependence (Heatherton et al., 1991); 5. Not currently on prescription medical or psychotropic medications 6. No current or past severe medical, endocrine or neurological illnesses including glaucoma, seizure disorders, hypertension, hypercholesterolemia as assessed by a complete medical history and physical 7. Not currently pregnant or breastfeeding 8. No history of significant radioactivity exposure in past year from another research study or occupation that exceeds RDRC guidelines 9. No metallic objects in the body that are contraindicated for MRI Healthy Controls (HC) 1. Males or females between 18 and 55 years old 2. No present or past DSM-5 disorders (other than nicotine dependence) 3. Criteria 5 to 9 as listed previously.
Where it's running
-
University of Pittsburgh
Pittsburgh, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Rajesh Narendran, MD — University of Pittsburgh
- Study coordinator: Rajesh Narendran, MD
- Email: narendranr@upmc.edu
- Phone: 4126475176
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HD-tDCS during CBT for Cocaine Use Disorder
This study tests whether adding high-definition transcranial direct current stimulation to cognitive behavioral therapy helps adults with cocaine use disorder see if CBT works better.
-
Imaging Brain Mitochondrial Complex-I in Cocaine Use Disorder
This study uses a PET scan with [F-18]BCPP-EF to see how mitochondrial Complex-I activity in the brain differs between people with cocaine use disorder and healthy controls.
-
Mild electrical brain stimulation (tDCS) with cognitive training to reduce cocaine cravings.
This trial will test whether brief sessions of mild electrical brain stimulation (tDCS) combined with cognitive reappraisal training can lower craving in adults receiving inpatient treatment for cocaine use disorder.
-
Clonidine to reduce craving in hospitalized people with cocaine or crack use disorder
This will try clonidine versus clonazepam to see if clonidine lowers craving in people hospitalized for cocaine or crack use disorder.
-
Semaglutide plus cognitive behavioral therapy for cocaine use disorder
This trial will test whether adding semaglutide (a GLP-1 medication) to cognitive behavioral therapy helps adults with cocaine use disorder reduce craving and use.
-
How cocaine use and stopping affects sleep and daily rhythms
This study tries to see how cocaine use and stopping change sleep and circadian rhythms in adults entering supervised inpatient detoxification.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.